Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.3% in the 1st quarter, HoldingsChannel.com reports. The fund owned 12,029 shares of the medical device company’s stock after buying an additional 30 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in DexCom were worth $4,323,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the company. Sands Capital Management LLC raised its stake in shares of DexCom by 28.2% during the first quarter. Sands Capital Management LLC now owns 2,936,502 shares of the medical device company’s stock valued at $1,055,349,000 after acquiring an additional 645,568 shares during the last quarter. Bluestein R H & Co. raised its stake in shares of DexCom by 23.8% during the first quarter. Bluestein R H & Co. now owns 57,279 shares of the medical device company’s stock valued at $20,585,000 after acquiring an additional 11,012 shares during the last quarter. Waddell & Reed Financial Inc. raised its stake in shares of DexCom by 15.5% during the first quarter. Waddell & Reed Financial Inc. now owns 880,183 shares of the medical device company’s stock valued at $316,329,000 after acquiring an additional 118,012 shares during the last quarter. Quadrant Capital Group LLC raised its stake in shares of DexCom by 19.3% during the first quarter. Quadrant Capital Group LLC now owns 401 shares of the medical device company’s stock valued at $144,000 after acquiring an additional 65 shares during the last quarter. Finally, Princeton Capital Management LLC bought a new position in shares of DexCom during the first quarter valued at about $368,000. 93.52% of the stock is owned by hedge funds and other institutional investors.
DXCM has been the subject of several recent analyst reports. Atlantic Securities assumed coverage on shares of DexCom in a research note on Thursday, April 15th. They set an “overweight” rating and a $438.00 price objective for the company. Raymond James boosted their price target on shares of DexCom from $449.00 to $466.00 and gave the company an “outperform” rating in a research report on Friday, April 30th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell boosted their price target on shares of DexCom from $480.00 to $488.00 and gave the company a “buy” rating in a research report on Friday, April 30th. TheStreet cut shares of DexCom from a “b-” rating to a “c” rating in a research report on Thursday, April 29th. Finally, Wells Fargo & Company upgraded shares of DexCom from an “underweight” rating to an “equal weight” rating and set a $380.00 price target on the stock in a research report on Friday, May 28th. Three analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $459.35.
In related news, insider Andrew K. Balo sold 2,391 shares of the stock in a transaction that occurred on Thursday, June 3rd. The shares were sold at an average price of $375.00, for a total transaction of $896,625.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Patrick Michael Murphy sold 500 shares of the stock in a transaction that occurred on Friday, March 26th. The shares were sold at an average price of $350.00, for a total transaction of $175,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,317 shares of company stock worth $20,044,335. Insiders own 0.52% of the company’s stock.
Shares of NASDAQ DXCM opened at $403.75 on Thursday. The business has a 50 day moving average price of $376.96. The company has a market capitalization of $39.05 billion, a P/E ratio of 79.17 and a beta of 0.76. DexCom, Inc. has a 52-week low of $305.63 and a 52-week high of $456.23. The company has a current ratio of 5.70, a quick ratio of 5.22 and a debt-to-equity ratio of 0.89.
DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 29th. The medical device company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.02. The firm had revenue of $505.00 million for the quarter, compared to the consensus estimate of $482.67 million. DexCom had a net margin of 25.36% and a return on equity of 17.86%. As a group, equities research analysts forecast that DexCom, Inc. will post 2.19 earnings per share for the current year.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system.
Recommended Story: Stocks Increasing Dividends
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).